Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HHMI’s Robert Lefkowitz Awarded 2012 Nobel Prize in Chemistry

Published: Thursday, October 11, 2012
Last Updated: Thursday, October 11, 2012
Bookmark and Share
Robert Lefkowitz and Brian K. Kobilka are the recipients of the 2012 Nobel Prize in Chemistry for studies of G-protein coupled receptors.

The Royal Swedish Academy of Sciences has announced that Robert J. Lefkowitz, a Howard Hughes Medical Institute (HHMI) investigator at Duke University, and Brian K. Kobilka of Stanford University School of Medicine are the recipients of the 2012 Nobel Prize in Chemistry for studies of G-protein coupled receptors.

According to the Academy, this year's Nobel Prize in Chemistry was awarded for discoveries that reveal the inner workings of an important family of such receptors: G-protein-coupled receptors.

For a long time, it remained a mystery how cells could sense their environment. Scientists knew that hormones such as adrenalin had powerful effects: increasing blood pressure and making the heart beat faster.

They suspected that cell surfaces contained some kind of recipient for hormones. But what these receptors actually consisted of and how they worked remained obscured for most of the 20th Century.

Cells in our body are constantly exposed to a variety of chemical signals-hormones, neurotransmitters, growth factors, and sometimes even drugs-that they need to interpret and translate into a response. This task is handled by receptors that dot cell membranes.

Lefkowitz, who became an HHMI investigator at Duke in 1976, essentially defined the field of receptor biology through his work with G protein-coupled receptors, the largest and most pervasive family of cell receptors.

A thousand or more of these receptors are known to exist throughout the body, playing critical roles in sight, smell, and taste, and in regulating heart rate, blood pressure, pain tolerance, glucose metabolism, and virtually all known physiological processes.

Surprisingly, Lefkowitz never fully intended to make research the focus of his career. As a child growing up in the Bronx, he read medical fiction and detective stories, and decided in third grade that he wanted to become a physician.

He went to medical school at Columbia University, finishing first in his class. But during a two-year fellowship at the National Institutes of Health from 1968-70, he got hooked on receptor biology, a field that was then in its infancy.

At that time, experiments in other laboratories had only suggested the presence of cell receptors, but no one had ever proved their existence.

Lefkowitz, however, was convinced they were real, and he set out to isolate them. Beginning with the β2-adrenergic receptor in 1982, Lefkowitz isolated eight of the nine subtypes of adrenergic receptors and determined their complete amino acid sequences.

The βadrenergic receptors are among the most common G protein-coupled receptors, regulating the body's fight-or-flight response by responding to epinephrine.

Lefkowitz also discovered two new families of proteins that desensitize G protein-coupled receptors-a finding that has helped scientists understand, in molecular terms, how receptors become tolerant to certain drugs.

The first is a novel family of enzymes called the G protein-coupled receptor kinases (GRKs) including the βadrenergic receptor kinase (βRK), and the second is a group of proteins called arrestins. Both protein families, he has shown, are widely distributed, and their actions are not limited to the β-adrenergic receptors.

Understanding the actions of arrestins and GRKs eventually may lead to new treatments for human diseases, including heart failure, Lefkowitz predicts. Recently his laboratory has discovered that the βarrestin/GRK system is actually bifunctional.

It serves as a signal transduction system by scaffolding various signaling systems such as MAP kinases or AKT to the receptors, even as it desensitizes G protein signaling.

Lefkowitz has found that it is possible to design drugs that, while serving as antagonists for G protein signaling, serve as agonists or stimulants of beneficial βarrestin-mediated signaling. Such "biased" ligands may represent an entirely novel class of therapeutic agents.

In addition to more than three decades of discoveries in the laboratory, Lefkowitz is widely recognized for his dedication to mentoring and his tireless devotion to his students. Over the years, he has trained several hundred graduate students and postdocs in his laboratory.

While acknowledging that there is no recipe for turning out successful researchers, Lefkowitz admits he is very much a "hands-on" mentor, one who enjoys daily interactions with those working in his laboratory.

In small group meetings held three or four times a week in his office, he discusses results and plots strategy with students working on related projects.

When it comes to his own research, Lefkowitz says he remains fascinated by the way it "continuously renews itself and always feels fresh. I come to work every day with a sense of great anticipation and curiosity about what new discoveries and insights will come our way. Every question that we can answer poses several new ones that seem even more interesting than the one we've just answered."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Spontaneous Mutations Play a Key Role in Congenital Heart Disease
New research shows that about 10 percent of these defects are caused by genetic mutations that are absent in the parents of affected children.
Monday, May 13, 2013
A New View of Transcription Initiation
Reading the human genome.
Monday, March 04, 2013
Search for Epigenetic Decoder in Brain Cells Leads Scientists to Rett Syndrome
New analysis suggests that MeCP2 recognizes 5hmC in the brain and facilitates activation of the genes.
Monday, December 31, 2012
Autism Gene Screen Highlights Protein Network for Howard Hughes Medical Institute Scientists
Over the past decade, scientists have added many gene mutations to the list of potential risk factors for autism spectrum disorders -- but researchers still lack a definitive explanation of autism’s cause.
Thursday, April 05, 2012
Protein-Folding Game Taps Power of Worldwide Audience to Solve Difficult Puzzles
Extended efforts could pay off in the design of new proteins that help fight disease, sequester carbon, or clean up the environment.
Monday, August 09, 2010
Mutations in Different Cells Cooperate to Set the Stage for Cancer
HHMI researchers have shown that distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors.
Friday, January 15, 2010
Scientists Identify New Genetic Culprit for Intellectual Disability
HHMI researchers identified a genetic mutation that plays a role in intellectual disability.
Monday, December 14, 2009
Sticklebacks Hone Defenses through Small DNA Deletions
A single genetic adjustment is enough to help a small fish make a big change, HHMI researchers find.
Friday, December 11, 2009
Studies Begin to Shape New Image of DNA
Researchers to develop a new picture of DNA that shows the molecule’s more dynamic side, which is capable of morphing into a large number of complex shapes.
Monday, November 09, 2009
Diagnosis Emerges from Complete Sequencing of Patient's Genes
HHMI researchers have identified a gene mutation that was responsible for the patient’s disease, but had not been suspected based on clinical observations.
Wednesday, October 28, 2009
Diagnosis Emerges from Complete Sequencing of Patient's Genes
Howard researchers used high-throughput DNA sequencing technology to identify a gene mutation that was responsible for the patient’s disease.
Tuesday, October 20, 2009
A Proliferation of Amyloid Arrangements
New research shows that variations in each fibril-forming protein’s arrangements may represent a protein-based system of inheritance between cells that parallels the genetic code.
Tuesday, August 25, 2009
Study Pinpoints Genetic Drivers of Lung Cancer’s Spread
Howard Hughes Medical Institute investigator find that lung cancer uses to seed deadly new tumors in the brain, bone marrow, and other organs.
Friday, July 03, 2009
New Strategy Reveals Targets for MicroRNA Gene Regulation
Researchers use HITS-CLIP technique to map the binding points of scores of different microRNAs throughout a genome in living mouse or human tissue.
Friday, June 19, 2009
New Studies Reveal Broad, Hidden Network that Lets Tumors Thrive
Howard researchers identify potential new drug targets for cancers long deemed “untouchable” due to the type of genetic mutation they contain.
Monday, June 01, 2009
Scientific News
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!